{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-004555","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2026-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.473772+00:00","generated_at":"2026-05-16T01:55:44.281355+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CervoMed's neflamapimod selected for UK EXPERTS-ALS platform for ALS trial","bullets":["Neflamapimod will be evaluated in EXPERTS-ALS, funded by UK NIHR and motor neuron disease charities, costs covered externally.","Initial phase: ~35 ALS patients for 18-24 weeks measuring neurofilament light chain (NfL) biomarker; potential expansion to 80.","First patient with ALS expected to be dosed by end of 2026; trial sponsored by Sheffield Teaching Hospitals NHS Foundation Trust.","CervoMed maintains primary focus on dementia with Lewy bodies (DLB); Phase 3 in DLB planned to start later in 2026.","Inclusion based on neflamapimod's p38 inhibition, ability to cross BBB, and positive prior clinical safety/biomarker data."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-004555","json":"https://secwatch.observer/filing/0001437749-26-004555.json","markdown":"https://secwatch.observer/filing/0001437749-26-004555.md","text":"https://secwatch.observer/filing/0001437749-26-004555.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926004555/0001437749-26-004555-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926004555/crvo20260218_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:55:44.281355+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}